ABL Diagnostics (XPAR:ABLD) Beneish M-Score: -2.64 (As of Jul. 06, 2026)


XPAR:ABLD ABL Diagnostics XPAR:ABLD
51 GF Score
Price €2.66
GF Value €7.71
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is ABL Diagnostics Beneish M-Score?

ABL Diagnostics XPAR:ABLD +0.76% 51 Beneish M-Score is -2.64 as of Jul. 06, 2026. GuruFocus rates XPAR:ABLD with a GF Score™ of 51/100 and a GF Value™ of €7.71 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 630 Healthcare Providers & Services companies, ABL Diagnostics ranks better than 55.24% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.64 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for ABL Diagnostics's Beneish M-Score or its related term are showing as below:

XPAR:ABLD' s Beneish M-Score Range Over the Past 10 Years
Min: -2.9   Med: -2.54   Max: -1.89
Current: -2.64

During the past 13 years, the highest Beneish M-Score of ABL Diagnostics was -1.89. The lowest was -2.90. And the median was -2.54.


ABL Diagnostics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for ABL Diagnostics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ABL Diagnostics Beneish M-Score Chart

ABL Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -2.37 -1.89 -2.64

ABL Diagnostics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.37 0.00 -1.89 0.00 -2.64

XPAR:ABLD vs VEEV, BTSG, TEM: Beneish M-Score Comparison

For the Health Information Services subindustry, ABL Diagnostics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ABL Diagnostics Beneish M-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where ABL Diagnostics's Beneish M-Score falls into.


XPAR:ABLD
51GF Score
ABL Diagnostics XPAR:ABLD
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ABL Diagnostics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of ABL Diagnostics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8176+0.528 * 0.9521+0.404 * 0.97+0.892 * 1.3039+0.115 * 1.0457
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * -0.040139-0.327 * 1.1226
=-2.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was €5.95 Mil.
Revenue was €6.95 Mil.
Gross Profit was €6.62 Mil.
Total Current Assets was €9.43 Mil.
Total Assets was €12.96 Mil.
Property, Plant and Equipment(Net PPE) was €0.42 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.61 Mil.
Selling, General, & Admin. Expense(SGA) was €0.00 Mil.
Total Current Liabilities was €3.92 Mil.
Long-Term Debt & Capital Lease Obligation was €1.40 Mil.
Net Income was €0.99 Mil.
Gross Profit was €0.00 Mil.
Cash Flow from Operations was €1.51 Mil.
Total Receivables was €5.58 Mil.
Revenue was €5.33 Mil.
Gross Profit was €4.84 Mil.
Total Current Assets was €8.43 Mil.
Total Assets was €11.81 Mil.
Property, Plant and Equipment(Net PPE) was €0.46 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.76 Mil.
Selling, General, & Admin. Expense(SGA) was €0.00 Mil.
Total Current Liabilities was €1.76 Mil.
Long-Term Debt & Capital Lease Obligation was €2.55 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(5.947 / 6.95) / (5.578 / 5.33)
=0.855683 / 1.046529
=0.8176

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(4.836 / 5.33) / (6.623 / 6.95)
=0.907317 / 0.95295
=0.9521

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (9.43 + 0.418) / 12.955) / (1 - (8.427 + 0.463) / 11.81)
=0.23983 / 0.247248
=0.97

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=6.95 / 5.33
=1.3039

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.757 / (0.757 + 0.463)) / (0.61 / (0.61 + 0.418))
=0.620492 / 0.593385
=1.0457

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 6.95) / (0 / 5.33)
=0 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.395 + 3.915) / 12.955) / ((2.553 + 1.759) / 11.81)
=0.40988 / 0.365114
=1.1226

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(0.987 - 0 - 1.507) / 12.955
=-0.040139

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

ABL Diagnostics has a M-score of -2.64 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.64 mean?
ABL Diagnostics (XPAR:ABLD) has a Beneish M-Score of -2.64 as of Jul. 06, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on ABL Diagnostics and its competitors. According to the industry distribution chart, ABL Diagnostics ranks #282 out of 630 companies in the Healthcare Providers & Services industry, placing it in the top 44.8%.
Is ABL Diagnostics' Beneish M-Score too high?
ABL Diagnostics' current Beneish M-Score is -2.64. Based on the distribution chart, ABL Diagnostics ranks #282 out of 630 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, ABL Diagnostics has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' Beneish M-Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #282 out of 630 companies for Beneish M-Score. This puts ABL Diagnostics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Healthcare Providers & Services company?
A good Beneish M-Score depends on the Healthcare Providers & Services industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on ABL Diagnostics and its competitors. ABL Diagnostics's current Beneish M-Score is -2.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.71, compared to a current price of €2.66 — trading 65.5% below its estimated fair value. The current Beneish M-Score is -2.64. ABL Diagnostics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current Beneish M-Score is -2.64 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?

Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued. The current stock price of €2.66 is trading 65.5% below its estimated GF Value™ of €7.71. GuruFocus considers ABL Diagnostics to be Significantly Undervalued.

Key valuation signals for XPAR:ABLD:

  • Beneish M-Score: -2.64
  • GF Value™: €7.71 vs. price of €2.66 (65.5% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ABL Diagnostics Business Description

Other Exchanges 9BK0:Germany
Address 72c, rue de, WOIPPY, Thionville, FRA, 57140
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
51GF Score

Get the complete analysis for XPAR:ABLD

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.66
Price
€7.71
GF Value